Corbus Pharmaceuticals (NASDAQ:CRBP) CEO Sells 17,000 Shares of Stock

Posted by Brian Himes on Aug 10th, 2026

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP – Get Free Report) CEO Yuval Cohen sold 17,000 shares of Corbus Pharmaceuticals stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $10.08, for a total value of $171,360.00. Following the completion of the transaction, the chief executive officer directly owned 157,316 shares of the company’s stock, valued at $1,585,745.28. This represents a 9.75% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Corbus Pharmaceuticals Trading Down 7.0%

NASDAQ CRBP traded down $0.71 on Monday, hitting $9.46. 335,692 shares of the company were exchanged, compared to its average volume of 327,211. Corbus Pharmaceuticals Holdings, Inc. has a 1-year low of $7.12 and a 1-year high of $20.56. The firm has a 50 day moving average of $8.72 and a two-hundred day moving average of $9.05. The company has a market cap of $175.29 million, a P/E ratio of -1.53 and a beta of 2.59.

Corbus Pharmaceuticals (NASDAQ:CRBP – Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($1.81) earnings per share for the quarter, missing the consensus estimate of ($1.26) by ($0.55). Research analysts anticipate that Corbus Pharmaceuticals Holdings, Inc. will post -4.87 EPS for the current fiscal year.

Hedge Funds Weigh In On Corbus Pharmaceuticals

Several large investors have recently bought and sold shares of CRBP. Velan Capital Investment Management LP raised its holdings in Corbus Pharmaceuticals by 3.4% during the third quarter. Velan Capital Investment Management LP now owns 61,000 shares of the biopharmaceutical company’s stock worth $772,000 after acquiring an additional 2,000 shares in the last quarter. Pale Fire Capital SE grew its stake in Corbus Pharmaceuticals by 14.5% in the first quarter. Pale Fire Capital SE now owns 21,350 shares of the biopharmaceutical company’s stock valued at $200,000 after purchasing an additional 2,700 shares in the last quarter. Mariner LLC grew its stake in Corbus Pharmaceuticals by 34.0% in the third quarter. Mariner LLC now owns 20,840 shares of the biopharmaceutical company’s stock valued at $264,000 after purchasing an additional 5,289 shares in the last quarter. Persistent Asset Partners Ltd bought a new position in Corbus Pharmaceuticals in the fourth quarter valued at approximately $54,000. Finally, ADAR1 Capital Management LLC acquired a new position in shares of Corbus Pharmaceuticals during the 3rd quarter worth approximately $129,000. 64.64% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. Oppenheimer lowered their price target on shares of Corbus Pharmaceuticals from $52.00 to $48.00 and set an “outperform” rating for the company in a report on Friday. Wedbush reduced their price objective on Corbus Pharmaceuticals from $38.00 to $30.00 and set an “outperform” rating on the stock in a report on Wednesday, May 27th. Jefferies Financial Group decreased their price objective on Corbus Pharmaceuticals from $36.00 to $33.00 and set a “buy” rating on the stock in a research report on Tuesday, May 12th. HC Wainwright lowered their target price on Corbus Pharmaceuticals from $40.00 to $35.00 and set a “buy” rating for the company in a research note on Friday. Finally, Mizuho cut their price target on Corbus Pharmaceuticals from $44.00 to $34.00 and set an “outperform” rating on the stock in a research note on Tuesday, June 23rd. Eight analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $41.12.

Check Out Our Latest Analysis on Corbus Pharmaceuticals

Corbus Pharmaceuticals Company Profile

(Get Free Report)

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of therapeutic candidates for rare, life-threatening inflammatory and fibrotic diseases. The company’s lead investigational therapy, lenabasum, is a synthetic, oral cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation by harnessing the body’s innate resolution pathways. Corbus operates by advancing small-molecule compounds through preclinical and clinical studies to address unmet medical needs in autoimmune and inflammatory disorders.

Lenabasum is currently under evaluation in a Phase 3 clinical trial for diffuse cutaneous systemic sclerosis (dcSSc) and in a Phase 2 study for cystic fibrosis–related inflammation.